New clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today…
Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility Pfizer Inc. (NYSE: PFE) today announced the company’s immediate efforts to provide relief and repair the damage caused to…
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S. Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $8 million…
New global action plan on epilepsy and other neurological disorders published WHO’s Intersectoral Global Action Plan (IGAP) on epilepsy and other neurological disorders, published today in all six UN languages, sets out…
FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental…
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) AbbVie (NYSE: ABBV) today announced the European Medicines Agency’s (EMA)…
Flagship Pioneering and Pfizer partner to accelerate development of innovative medicines targeting unmet needs Flagship Pioneering, Inc. and Pfizer Inc. (NYSE: PFE) today announced the companies have partnered to create…
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health AstraZeneca has announced a $400 million investment in its global AZ Forest programme,…
Positive Phase III results for Roche’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase…
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries Gilead Sciences, Inc. (Nasdaq: GILD) is pleased to…
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug…
AbbVie secures positive CHMP opinion for atogepant for the preventive treatment of adults with migraine AbbVie (NYSE: ABBV) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for…